News Wire

In a new report, the American Hospital Association (AHA) states that centers must cut down on paperwork and other bureaucratic exercises that can cause health care costs to mount. The group suggests that hospitals convert many of these processes to an electronic format, particularly with regard to verification…
The FDA has approved eribulin mesylate (Halaven, Eisai), a form of chemotherapy, for the treatment of unresectable or metastatic liposarcoma, a type of soft-tissue sarcoma (STS). The treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. STS is a disease…
The World Health Organization (WHO) expects the Zika virus, which is spreading through the Americas, to affect between three million and four million people, according to a Reuters report. There is no vaccine or treatment for the infection, which is related to dengue and chikungunya. Symptoms include…
Only 1% of U.S. doctors are responsible for 32% of the malpractice claims that result in payments to patients, according to an analysis of 15 years’ worth of cases. And when a doctor has to pay out on one claim, the chances are good that the same physician will soon be paying out on another, researchers…
The FDA has given the green light to Adzenys XR-ODT (Neos Therapeutics) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients 6 years of age and older. With this approval, the product is the first extended-release orally disintegrating tablet (ODT) for this indication. Adzenys…
Low-dose chlorthalidone reduced ambulatory blood pressure (ABP) in patients with stage-1 hypertension, whereas low-dose hydrochlorothiazide (HCTZ) resulted in masked hypertension, according to a new study published in the February 2016 issue of the Journal of the American College of Cardiology. Anil…
The FDA has approved Dexilant SoluTab delayed-release orally disintegrating tablets (Takeda Pharmaceuticals U.S.A.), a new formulation of dexlansoprazole that can be taken by allowing the tablet to melt in the patient’s mouth. The product is a proton pump inhibitor (PPI) indicated for the treatment…
The Centers for Disease Control and Prevention (CDC) has added the U.S. Virgin Islands and Dominican Republic  to its Zika virus travel alerts. Previously, the agency issued an alert for people traveling to the following regions and countries where Zika virus transmission is ongoing: the Commonwealth…
In 2009, HealthCare Partners Affiliates Medical Group, based in Southern California, launched House Calls, an in-home program that provides, coordinates, and manages care primarily for recently discharged high-risk, frail, and psychosocially compromised patients. The program’s aim is to reduce preventable…
The U.S. Preventive Services Task Force (USPSTF) has released a final recommendation statement on screening for depression in adults. The task force found evidence that screening in the primary care setting is beneficial and recommends that clinicians screen all adults for depression. The recommendation…
Results have been announced from the LUX-Lung 7 trial. Superiority in progression-free survival (PFS) and time to treatment failure was demonstrated with the second-generation epidermal growth factor receptor (EGFR)-directed therapy afatinib (Gilotrif, Boehringer Ingelheim) compared with first-generation…
The FDA has accepted for review a biologics license application for IVIG-SN (human normal immunoglobulin G for intravenous administration, Green Cross Corporation) intended for the treatment of primary immunodeficiency diseases (PIDs). The Prescription Drug User Fee Act (PDUFA) date for the FDA to complete…
The World Health Organization has announced that Zika virus infection, a mosquito-borne illness that in the past year has swept quickly throughout equatorial countries, is expected to spread across the Americas and into the U.S. The symptoms of the disease include a rash, headache, and mild fever. However,…
The FDA has accepted for review the biologics license application (BLA) for ABP 501 (Amgen), a biosimilar candidate to adalimumab (Humira, AbbVie). The BLA, submitted on November 25, 2015, is based on analytical, clinical, and pharmacokinetic data. Phase 3 comparative efficacy and safety studies were…
Naturally occurring clay from British Columbia, Canada –– long used by the region's Heiltsuk First Nation for its healing potential –– exhibits potent antibacterial activity against multidrug-resistant pathogens, according to researchers at the University of British Columbia. The team recommends…

Pages